Plain-English translation of NCT06196697 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination of two immunotherapy medications called and , given alongside standard chemotherapy drugs (either or ), to treat advanced gastric cancer or cancer at the junction between the stomach and esophagus. The trial will first test different doses of the medications to find the safest and most effective combination, then enroll more patients to confirm how well this treatment works.
Advanced stomach cancers are very difficult to treat and patients often have limited options. This medication combination aims to help the body's immune system fight the cancer more effectively when combined with traditional chemotherapy, potentially offering a new treatment path for patients who have never received systemic therapy before.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous (IV) infusions of the two immunotherapy medications on a regular schedule, combined with chemotherapy drugs taken either intravenously or by mouth in 3-week cycles for up to 6 cycles. You will need to attend regular clinic visits for treatment, blood work, and imaging scans to monitor how well the treatment is working and to watch for side effects. The trial involves careful dose monitoring in the early stages to ensure safety before enrolling additional patients.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China